Vaccinex, Inc. VCNX Income Statement

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Sep'17	Jun'17
Revenue
-	523	717	511	612	724	0	0	0	-	-
Costs and expenses:
Cost of revenue
-	199	500	738	968	1,033	0	0	0	-	-
Research and development
23,667	25,670	28,332	27,103	25,311	22,353	0	0	0	0	0
General and administrative
6,772	6,669	6,122	5,683	5,045	4,619	0	0	0	0	0
Total costs and expenses
30,463	32,538	34,954	33,524	31,324	28,005	0	0	0	0	0
Loss from operations
-30,034	-32,015	-34,237	-33,013	-30,712	-27,281	0	0	0	0	0
Change in fair value of derivative liabilities
-	-	-	-	-	369	0	0	0	0	0
Interest expense
-	-	-	-	-	392	0	0	0	0	0
Loss on extinguishment of related party convertible promissory note
-	-	-	-	-	-2,379	0	0	0	-	-
Other income (expense), net
89	152	251	282	252	165	0	0	0	-	0
Loss before provision for income taxes
-29,945	-31,863	-33,986	-32,943	-30,723	-29,518	0	0	0	0	0
Provision for income taxes
0	0	0	0	0	0	0	0	0	0	-
Net loss
-29,945	-31,863	-33,986	-32,943	-30,723	-29,518	0	0	0	0	0
Net loss attributable to noncontrolling interests
0	0	0	0	0	0	0	0	0	-	-
Net loss attributable to Vaccinex, Inc. common stockholders
-29,945	-31,863	-32,136	-31,102	0	-	0	0	-	0	0
Comprehensive loss
0	-	-	-	0	-	-	-	-	-	-
Cumulative dividends on redeemable preferred stock
-	-	-	-	-	-	-	0	-	0	0
Net loss attributable to Vaccinex, Inc. common stockholders, basic and diluted
-	-	-33,186	-32,143	-	-	0	0	0	0	0
Net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted
-0.45	-0.35	-0.56	-0.77	-0.79	9.13	-0.93	-6.72	-7.13	-5.75	-5.15
Weighted-average shares used in computing net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted
16,001	14,808	13,759	11,479	11,475	11,610	7,078	1,103	1,102	1,102	1,101